---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-061608"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T03:11:59.775283+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Adagio CMO Lynn Connolly resigns; Hershberger takes over clinical development

## Summary
- CMO Lynn Connolly resigns effective March 25, 2022, to tend to family obligations.
- Connolly remains through ADG20 Phase 2/3 data analysis and transition of duties.
- Chief Development Officer Ellie Hershberger permanently assumes responsibility for clinical development programs.
- Company expects to enter into a consulting agreement with Dr. Connolly.

## SEC filing metadata
- accession: 0001193125-22-061608
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312522061608/0001193125-22-061608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312522061608/d656486d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-061608
- JSON: https://secwatch.observer/filing/0001193125-22-061608.json
- Plain text: https://secwatch.observer/filing/0001193125-22-061608.txt

## Key facts
- Executive change
  Lynn Connolly resigned as Chief Medical Officer at Invivyd, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: Lynn Connolly, M.D., Ph.D., Chief Medical Officer of Adagio Therapeutics, Inc. (the “Company”), has resigned her position, effective as of March 25, 2022, to tend to family obligations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832038/000119312522061608/0001193125-22-061608-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.